A large study recruited patients from multiple nations in four cohorts receiving CD19 targeted CAR Ts with TRAC and β2M KO for relapsed/refractory B cell malignancies (A-C: NHL, D: B-ALL) and was terminated early in phase II [249]. Here, B2M is linked to non-Hodgkin lymphoma.